A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal
Purpose: to evaluate the efficacy and toxicity of a concomitant treatment using EGFR-TKI and
thoracic radiation in elderly patients with esophageal Cancer.
Methods:Patients(>70 years old) with esophageal Cancer will receive thoracic radiation
therapy 54-60 Gy over 30 fractions and concurrent with gefitinib 250mg/day.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response rate
1 month after the thoracic radiotherapy and concurrent gefitinib treatment
Mao Weimin, MD
Zhejiang Cancer Hospital
China: Food and Drug Administration